OrlandoMay 15 - 20EASL Congress 2026
BarcelonaMay 27 - 30ASCO 2026ChicagoMay 29 - Jun 2EULAR 2026
ViennaJun 3 - 6EHA 2026
MilanJun 11 - 14BIO 2026San DiegoJun 16 - 19ENDO 2026BostonJun 18 - 21ADA 2026San FranciscoJun 19 - 22ESC 2026
LisbonAug 28 - Sep 1EASD 2026MadridSep 9 - 12ERS 2026
CopenhagenSep 12 - 15ESMO 2026
BerlinSep 12 - 16ECTRIMS 2026BarcelonaSep 17 - 20UEG Week 2026ViennaOct 3 - 7AHA 2026ChicagoNov 7 - 9ACR 2026Washington DCNov 14 - 19ASH 2026New OrleansDec 12 - 15ACC.27 Together With WCCHoustonApr 10 - 12ATS 2026OrlandoMay 15 - 20EASL Congress 2026BarcelonaMay 27 - 30ASCO 2026ChicagoMay 29 - Jun 2EULAR 2026ViennaJun 3 - 6EHA 2026MilanJun 11 - 14BIO 2026San DiegoJun 16 - 19ENDO 2026BostonJun 18 - 21ADA 2026San FranciscoJun 19 - 22ESC 2026LisbonAug 28 - Sep 1EASD 2026MadridSep 9 - 12ERS 2026CopenhagenSep 12 - 15ESMO 2026BerlinSep 12 - 16ECTRIMS 2026BarcelonaSep 17 - 20UEG Week 2026ViennaOct 3 - 7AHA 2026ChicagoNov 7 - 9ACR 2026Washington DCNov 14 - 19ASH 2026New OrleansDec 12 - 15ACC.27 Together With WCCHoustonApr 10 - 12
Ebola Pandemic Risk in 2026: A Low Probability Assessment
An Ebola pandemic in 2026 is considered unlikely due to established public health responses, vaccine availability, and improved surveillance.
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates significant efficacy in chronic weight management, offering a new therapeutic option.
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
Managing hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) presents diagnostic and therapeutic challenges.
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
Extracellular vesicles (EVs) and particles (EPs) offer new avenues for cancer diagnosis, prognosis, and therapy. Their role as biomarkers and drug delivery systems is expanding.
IVUS Guidance Improves PCI Outcomes in Complex Bifurcation Lesions
Intravascular ultrasound (IVUS) guidance for percutaneous coronary intervention (PCI) in complex bifurcation lesions demonstrated superior outcomes compared to angiography guidance.
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
Late-onset genetic cholestatic diseases are frequently missed in adults, leading to delayed diagnosis and suboptimal management. Increased awareness is critical.
PARP1 Deficiency Reduces Amyloid Pathology in Familial AD Model
New preclinical work links PARP1 deficiency to reduced amyloid burden and cognitive preservation in a familial Alzheimer's model.
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
ATS 2026 highlights advancements in nontuberculous mycobacteria (NTM) lung disease, focusing on improved detection, optimized therapy, and patient quality of life.
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
New Biologic Offers Option for Severe Eosinophilic Asthma
Pediatric Pulmonary Research Gaps Highlighted for Global Health
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
ILD Diagnosis and Management: A Practical ATS 2026 Update
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
Pediatric Advanced Bronchoscopy: Precision in Airway Management
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
Immunological Insights Inform ILD & Transplant Outcomes
ATS 2026: Ultrasound Education Advances for Clinical Practice
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
Sarcoidosis: Current Understanding of Diagnosis and Management
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
Ventilator Management: Foundations for Bedside Implementation
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
Triple Therapy Optimises COPD Outcomes at ATS 2026
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
Epithelial Dysfunction: A Unified Target in Airway Disease Management
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
New Biologic Offers Option for Severe Eosinophilic Asthma
Pediatric Pulmonary Research Gaps Highlighted for Global Health
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
ILD Diagnosis and Management: A Practical ATS 2026 Update
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
Pediatric Advanced Bronchoscopy: Precision in Airway Management
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
Immunological Insights Inform ILD & Transplant Outcomes
ATS 2026: Ultrasound Education Advances for Clinical Practice
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
Sarcoidosis: Current Understanding of Diagnosis and Management
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
Ventilator Management: Foundations for Bedside Implementation
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
Triple Therapy Optimises COPD Outcomes at ATS 2026
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
Epithelial Dysfunction: A Unified Target in Airway Disease Management
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
EASL 2026 Skills Learning Centre will address variceal bleeding, highlighting current evidence for endoscopic and pharmacological interventions.
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
EASL 2026 will feature a Skills Learning Centre on liver and spleen elastography, highlighting its role in non-invasive fibrosis assessment.
EASL 2026 Forum: Enhancing Patient-Clinician Communication
The EASL 2026 Patient & Advocate Forum addresses critical gaps in patient-clinician communication and interprofessional collaboration.
EASL 2026: Alcohol Policy Action Needed for Liver Disease
6 min readA-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
6 min readMASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
5 min readEASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
7 min readLate-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
6 min readHDV Management: EASL 2026 Highlights PegIFN-α as Standard
6 min readRight Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
ATS 2026 session addresses persistent challenges in right heart catheterization waveform interpretation, offering a structured approach to reduce diagnostic ambiguity.
Primary LV Unloading in Anterior STEMI Shows No Benefit in STEMI-Door to Unload Trial
The STEMI-Door to Unload trial found no benefit for primary left ventricular unloading in anterior STEMI without cardiogenic shock.
DISCOVER INOCA Defines Vasomotor Disorders in Nonobstructive CAD
The DISCOVER INOCA registry provides a comprehensive definition of coronary vasomotor disorders in patients with ischemia and nonobstructive coronary arteries (INOCA).
Sex Differences in MINOCA Causes Identified by OCT and CMR Imaging
7 min readORBITA-CTO: CTO PCI Offers No Angina Relief Over Placebo
6 min readFFR or 3D-QCA Guided Revascularisation: The FAST III Trial
5 min readSURVIV: Transcatheter Valve-in-Valve Non-Inferior to Redo-Surgery for Mitral Bioprosthetic Dysfunction
6 min readPRO-TAVI: Deferring PCI Before TAVI Non-Inferior to Routine PCI
5 min readEmboliner Non-Inferior to Sentinel for TAVR Cerebral Protection
7 min readTirzepatide: Efficacy in Weight Management Explored at ATS 2026
Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates significant efficacy in chronic weight management, offering a new therapeutic option.
Lower-Dose Tirzepatide: Can It Sustain Weight Loss Long-Term?
New evidence examines whether reduced tirzepatide doses can maintain weight loss, with implications for long-term obesity management in primary care.
Oral Orforglipron Sustains Weight Loss After Injectable GLP-1 Therapy
The ATTAIN-MAINTAIN trial shows oral orforglipron preserves most injectable-achieved weight loss at 52 weeks, offering a scalable transition option.
GLP-1 Drugs and Oral Medication Absorption: What Prescribers Need to Know
4 min readWhat Still Eludes Us in MASH Research?
1 min readLorlatinib and New-Onset Diabetes Practical Monitoring for Oncologists
1 min readLorlatinib and the Enigma of Autoantibody-Negative Diabetes
1 min readUnraveling MASH: Implications for Clinical Practice
1 min readSGLT2 Inhibitors: Promise and Peril in Prader-Willi Syndrome?
1 min readPARP1 Deficiency Reduces Amyloid Pathology in Familial AD Model
New preclinical work links PARP1 deficiency to reduced amyloid burden and cognitive preservation in a familial Alzheimer's model.
Brain Cooling After Thrombectomy: Does Hypothermia Aid LVO Recovery?
Targeted temperature management after mechanical thrombectomy for LVO stroke is under active investigation, but the evidence base remains preliminary.
Gut Microbiota Signal the Brain via the Vagus Nerve: What GPs Should Know
The gut-brain axis operates partly through vagal afferent neurons. Here is what the established mechanistic evidence means for everyday practice.